PeritonTreat

PeritonTreat is a Russian biotechnology company based in Ufa, Republic of Bashkortostan, and a resident of the Skolkovo Foundation's Biomedical Technologies Cluster. Founded in 2013, the company is dedicated to developing novel intraperitoneal (IP) cancer immunotherapies based on dehydroxymethylepoxyquinomicin (DHMEQ), a highly specific small molecule inhibitor of the transcription factor NF-kappa B (NF-κB). PeritonTreat's lead program focuses on the intraperitoneal administration of DHMEQ, which targets inflammatory cells in the peritoneal cavity to treat difficult-to-manage cancers such as ovarian, prostate, breast, and pancreatic carcinomas, as well as severe inflammatory conditions. The company operates in collaboration with Bashkortostan State Medical University and international partners, including OncoTech, to advance its therapeutic pipeline toward clinical application.